Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer

Дата публикации: 01-08-2026 00:00:00

This nonrandomized clinical trial examines the efficacy and toxic effects of immune checkpoint inhibitors in combination with quad-shot radiotherapy for patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	PDS0101 With Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	0	10.08	17-09-2026
2	Is Antigen-Specific Immunotherapy a New Frontier in HPV-Initiated Head and Neck Cancer?	0	10.94	17-09-2026
3	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
4	Pembrolizumab Plus Chemotherapy for Cervical Cancer	0	14.76	10-09-2026
5	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
6	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
7	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
8	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
9	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023
10	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.64. Источник: jamanetwork.com.